Drug
MGN1703 clinical trials
Also written MGN1703.
- studies test it
- 6
- open now
- 0
- in phase 3
- 1
- first study started
- 2010
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 3
Mologen AG (3) · University of Aarhus (2) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MGN1703 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesTerminatedPhase 1M.D. Anderson Cancer CenterNCT02668770Written as MGN1703
- Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIVCompletedPhase 2University of AarhusNCT03837756Written as Lefitolimod
- Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentStatus unknownPhase 3Mologen AGNCT02077868Written as MGN1703 treatment
- Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLCCompletedPhase 2Mologen AGNCT02200081Written as MGN1703
- Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 InfectionCompletedPhase 1/2University of AarhusNCT02443935Written as MGN1703
- Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal CarcinomaCompletedPhase 2Mologen AGNCT01208194Written as MGN1703